Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1975180
                    [Title] => Long-acting Beta2 agonists didn’t boost BP in COPD
                    [Summary] => Neither heart rate nor blood pressure worsened under long-term use of long-acting beta2 agonists olodaterol or formoterol in patients with chronic obstructive pulmonary disease, according to a post hoc pooled analysis published in Pulmonary Pharmacology & Therapeutics.
                    [DatePublished] => 2019-12-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

Pulmonary Pharmacology & Therapeutics.

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1975180
                    [Title] => Long-acting Beta2 agonists didn’t boost BP in COPD
                    [Summary] => Neither heart rate nor blood pressure worsened under long-term use of long-acting beta2 agonists olodaterol or formoterol in patients with chronic obstructive pulmonary disease, according to a post hoc pooled analysis published in Pulmonary Pharmacology & Therapeutics.
                    [DatePublished] => 2019-12-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Long-acting Beta2 agonists didn’t boost BP in COPD

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | December 8, 2019 - 12:00am

Neither heart rate nor blood pressure worsened under long-term use of long-acting beta2 agonists olodaterol or formoterol in patients with chronic obstructive pulmonary disease, according to a post hoc pooled analysis...

Opinion